GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Santhera Pharmaceuticals Holding AG (OTCPK:SPHDF) » Definitions » Book Value per Share

Santhera Pharmaceuticals Holding AG (Santhera Pharmaceuticals Holding AG) Book Value per Share : $-5.17 (As of Jun. 2023)


View and export this data going back to 2008. Start your Free Trial

What is Santhera Pharmaceuticals Holding AG Book Value per Share?

Santhera Pharmaceuticals Holding AG's book value per share for the quarter that ended in Jun. 2023 was $-5.17.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Santhera Pharmaceuticals Holding AG was 86.30% per year. The lowest was -78.30% per year. And the median was -30.00% per year.

Santhera Pharmaceuticals Holding AG's current price is $11.70. Its book value per share for the quarter that ended in Jun. 2023 was $-5.17. Hence, today's PB Ratio of Santhera Pharmaceuticals Holding AG is .

During the past 13 years, the highest P/B Ratio of Santhera Pharmaceuticals Holding AG was 57.09. The lowest was 0.50. And the median was 4.73.


Santhera Pharmaceuticals Holding AG Book Value per Share Historical Data

The historical data trend for Santhera Pharmaceuticals Holding AG's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Santhera Pharmaceuticals Holding AG Book Value per Share Chart

Santhera Pharmaceuticals Holding AG Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Book Value per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 26.44 19.37 -3.95 0.29 -7.12

Santhera Pharmaceuticals Holding AG Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.25 0.29 -2.63 -7.12 -5.17

Competitive Comparison of Santhera Pharmaceuticals Holding AG's Book Value per Share

For the Biotechnology subindustry, Santhera Pharmaceuticals Holding AG's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Santhera Pharmaceuticals Holding AG's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Santhera Pharmaceuticals Holding AG's PB Ratio distribution charts can be found below:

* The bar in red indicates where Santhera Pharmaceuticals Holding AG's PB Ratio falls into.



Santhera Pharmaceuticals Holding AG Book Value per Share Calculation

Santhera Pharmaceuticals Holding AG's Book Value Per Share for the fiscal year that ended in Dec. 2022 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-46.89-0.00)/6.59
=-7.12

Santhera Pharmaceuticals Holding AG's Book Value Per Share for the quarter that ended in Jun. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-47.49-0.00)/9.20
=-5.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Santhera Pharmaceuticals Holding AG  (OTCPK:SPHDF) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Santhera Pharmaceuticals Holding AG Book Value per Share Related Terms

Thank you for viewing the detailed overview of Santhera Pharmaceuticals Holding AG's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Santhera Pharmaceuticals Holding AG (Santhera Pharmaceuticals Holding AG) Business Description

Traded in Other Exchanges
Address
Hohenrainstrasse 24, Pratteln, CHE, 4133
Santhera Pharmaceuticals Holding AG is a specialty pharmaceutical company focused on the development and commercialization of products for the treatment of mitochondrial and neuromuscular diseases, an area that includes many orphan and niche indications with high unmet medical needs. It has one operating segment, namely the development and commercialization of products for the treatment of neuro-ophthalmological, pulmonary, and neuromuscular diseases. The company derives most of its revenue from the European Union.